Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 11/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.65 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15734537 | 1.00 | OPRD1 (0.82) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8418756 | 0.93 | OPRM1 (0.76) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL12085066 | 0.91 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL680036 | 0.91 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL29349768 | 0.91 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL29408441 | 0.91 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL26237 | 0.91 | OPRD1 (0.69) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL7664620 | 0.90 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL1649977 | 0.90 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| Nicomorphine SCHEMBL395672 | 0.90 | OPRD1 (0.68) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691989-B2 | Methods of synthesis of morphinans | PHOENIX PHARMALABS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691989-B2 | Methods of synthesis of morphinans | PHOENIX PHARMALABS, INC. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2303892-A1 | METHODS OF SYNTHESIS OF MORPHINANS | Phoenix Pharmalabs, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20090318699-A1 | Methods of synthesis of morphinans | PHOENIX PHARMALABS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318699-A1 | Methods of synthesis of morphinans | PHOENIX PHARMALABS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318699-A1 | Methods of synthesis of morphinans | PHOENIX PHARMALABS, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009154673-A1 | METHODS OF SYNTHESIS OF MORPHINANS | PHOENIX PHARMALABS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154673-A1 | METHODS OF SYNTHESIS OF MORPHINANS | PHOENIX PHARMALABS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318699-A1 | Methods of synthesis of morphinans | NCL, RTCB, MMAB | OPRD1 750/4885OPRM1 79/4885OPRK1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.